CN101461895B - Medicament composition for treating female climacteric syndrome and delaying age - Google Patents
Medicament composition for treating female climacteric syndrome and delaying age Download PDFInfo
- Publication number
- CN101461895B CN101461895B CN2007103020416A CN200710302041A CN101461895B CN 101461895 B CN101461895 B CN 101461895B CN 2007103020416 A CN2007103020416 A CN 2007103020416A CN 200710302041 A CN200710302041 A CN 200710302041A CN 101461895 B CN101461895 B CN 101461895B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- weight
- radix
- weight portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a pharmaceutical composition for treating female climacteric syndrome and delaying senility. The pharmaceutical composition is prepared from epimedium, glossy privet fruit, fragrant solomonseal rhizome, black bean, flower of Chinese scholartree, astragalus root, angelica, medlar, dogwood, prepared rhizome of rehmannia, fleece-flower root, and royal jelly freeze-drying powder. The raw material drugs are added with the prior auxiliary material, and are prepared into various clinically acceptable dosage forms by the prior process, such as capsule, granule, tablet, oral liquid preparation, water injection or dry powder injection. The invention also provides application of the pharmaceutical composition to prepare medicaments for treating the female climacteric syndrome and delaying the senility, enhancing immune function, and increasing bone density.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, particularly a kind of pharmaceutical composition for the treatment of female dimacteric syndrome and slow down aging, enhancing immunity, bone density improving.
Background technology
After the women enters into the climacteric period, occur easily with hectic fever, hyperhidrosis, cardiopalmus, unstable blood pressure, dizziness, tinnitus, irritability, insomnia, forgetful, constipation, symptom such as tired, be referred to as climacteric syndrome.The sickness rate of diseases such as osteoporosis, blood fat rising, atherosclerotic, diabetes, coronary heart disease and apoplexy also obviously raises in addition.Because these, associated conditions caused estrogen secretion minimizing closely related with the ovarian function decline climacteric, therefore, western medical treatment mainly is a complementing estrogen.This " hormone replacement therapy " be extensive use more than 30 year so far, can effectively improve some symptoms of climacteric syndrome, but life-time service may increase breast carcinoma and onset of endometrial cancer rate.
Chinese medicine is generally pressed sick category such as the traditional Chinese medical science " menopausal syndrome ", " hysteria ", " melancholia " to the research of Women, carry out Study of pathogenesis, clinically, take determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs more, add and subtract with card, comprehensive each family's report, each family gives priority to, and has from the kidney opinion to control, and adopts LIUWEI DIHUANG WAN, ZHIBAI DIHUANG WAN, Yougui Wan, the kidney-Yang-Reinforcing Bolus, ERXIAN TANG more; Control from the liver opinion, adopt Sini San and ERZHI WAN, bupleurum powder for relieving liver-qi, Danzhi Xiaoyao San, YIGUANJIAN etc. to change sanction more; Control from the spleen opinion, adopt five tastes Yigong San powder with marveous Effect, tonifying the spleen drink, Fuzi Lizhong Wan etc. more; Control from the lung opinion, adopt baihe gujin decoction, Radix Glycyrrhizae Rhizoma Zingiberis soup, the BUFEI TANG side of closing plus-minus more; Control from heart opinion, adopt mind-easing tonic bolus with arborvitate seed more; The five internal organs combination of syndromes opinion is controlled, and adopts LIUWEI DIHUANG WAN more, YIGUANJIAN, Yougui Wan, the kidney-Yang-Reinforcing Bolus, the safe ball of friendship, GUIPI TANG, XIAOYAO POWDER etc.These add and subtract medication, the effect of the clinical climacteric syndrome that has clear improvement, but individuation is strong, is difficult for the scientific research of standardization, so that the judgement that affects the treatment.At present, domestic many medical colleges have carried out positive explore research, many achievements are introduced to the market as Chinese patent medicine, as the climacteric health of GENGNIANAN coated tablet, the production of White Cloud Mountain, Guangzhou pharmaceutical factory, the loyal granule in ground that lobe ZHENHELING PIAN, Hunan Province medical university are given birth to by Chinese medicine three factories in Shanghai City city.Yu Zhimin pushes away a piece of writing, deficiency of the kidney yin type climactero tablet, woman's Yiganning capsule, climacteric Menstruation-Regulating Capsule sheet; Kidney yang deficiency syndrome is suitable for climacteric and finds pleasure in, joins stilbene Hydrargyri Oxydum Rubrum sheet, Herba Cistanches the kidney invigorating ball.Pacify hectic fever sweating, insomnia and dreamful sleep, the susceptible to lose temper due to restlessness of year climacteric sheet to climacteric syndrome, dizziness headache, hypomnesis and blood pressure balance etc. has obvious curative effects.Jin Xiangshu etc. transfer liver soup comprehensive 65 examples of treatment climacteric with nourishing kidney, Zhang Xinyong the kidney invigorating soup treatment primary disease 53 examples that nourish heart.
Summary of the invention
The object of the invention is to provide a kind of pharmaceutical composition, and another purpose of the present invention is to provide the purposes of this pharmaceutical composition.
The present invention seeks to be achieved through the following technical solutions
The crude drug of pharmaceutical composition of the present invention consists of:
Herba Epimedii 15-35 weight portion Fructus Ligustri Lucidi 10-20 weight portion Rhizoma Polygonati Odorati 5-15 weight portion
Semen sojae atricolor 5-15 weight portion Flos Sophorae 5-15 weight portion Radix Astragali 1-5 weight portion
Radix Angelicae Sinensis 1-10 weight portion Fructus Lycii 1-10 weight portion Fructus Corni 1-10 weight portion
Radix Rehmanniae Preparata 1-10 weight portion Radix Polygoni Multiflori 1-10 weight portion freeze-dried royal jelly powder 1-5 weight portion.
Above-mentioned raw materials medicine preferred weight proportioning is as follows:
Herba Epimedii 25 weight portion Fructus Ligustri Lucidi 15 weight portion Rhizoma Polygonati Odorati 10 weight portions
The Semen sojae atricolor 10 weight portion Flos Sophoraes 10 weight portion Radixs Astragali 2.5 weight portions
Radix Angelicae Sinensis 5 weight portion Fructus Lycii 5 weight portion Fructus Corni 5 weight portions
Radix Rehmanniae Preparata 5 weight portion Radix Polygoni Multiflori 5 weight portion freeze-dried royal jelly powders 2.5 weight portions.
Above-mentioned raw materials medicine preferred weight proportioning is as follows:
Herba Epimedii 16 weight portion Fructus Ligustri Lucidi 18 weight portion Rhizoma Polygonati Odorati 6 weight portions
The Semen sojae atricolor 14 weight portion Flos Sophoraes 7 weight portion Radixs Astragali 4 weight portions
Radix Angelicae Sinensis 2 weight portion Fructus Lycii 9 weight portion Fructus Corni 3 weight portions
Radix Rehmanniae Preparata 8 weight portion Radix Polygoni Multiflori 4 weight portion freeze-dried royal jelly powders 4 weight portions.
Above-mentioned raw materials medicine preferred weight proportioning is as follows:
Herba Epimedii 32 weight portion Fructus Ligustri Lucidi 12 weight portion Rhizoma Polygonati Odorati 14 weight portions
The Semen sojae atricolor 6 weight portion Flos Sophoraes 13 weight portion Radixs Astragali 2 weight portions
Radix Angelicae Sinensis 9 weight portion Fructus Lycii 2 weight portion Fructus Corni 8 weight portions
Radix Rehmanniae Preparata 3 weight portion Radix Polygoni Multiflori 7 weight portion freeze-dried royal jelly powders 2 weight portions.
Get pharmaceutical composition above-mentioned raw materials medicine of the present invention, add conventional adjuvant, be prepared into clinical acceptable various dosage forms according to common process, as: capsule, granule, tablet, oral liquid, aqueous injection or lyophilized injectable powder.
Pharmaceutical composition of the present invention is a kind of based on the Chinese medicine the kidney invigorating, be used for Women, it is characterized in that having " integration of edible and medicinal herbs ", " control synchronously " pure Chinese medicine compound, improving the Women health quality, improve Women syndrome, osteoporosis, raising immunologic function, defying age, improving the equal tool in cardiovascular function aspect and significantly act on.Drug combination preparation of the present invention has that consumption is little, active ingredient is high, it is safe, with strong points to take, suitable crowd characteristics widely.
Pharmaceutical composition of the present invention is according to the theory of the original medical science-Chinese medicine and pharmacy of China: " the kidney invigorating gas benefit natural life-span ", " the food medicine in like manner ", " kidney governing reproduction ", " kidney governing bones ", " kidney storing essence, secrete menses ", theory, the nourishing YIN with the kidney invigorating gas, support essence and blood to contain sun, reach " YIN and YANG in a relative equilibrium; spirit and even ", thereby improve environment in the climacteric physiology, reach raising and improve Women syndrome, osteoporosis, raising immunologic function, defying age, improve cardiovascular function.This research experiment and the clinical matched group of all establishing, wherein with the comparative study of HRT method, it acts on suitable and asexual hormone side effect.
Per os gives the medicament composition capsule preparation 30d of the present invention of mice various dose, can improve mouse thymus body weight ratio, and the humoral immune function of mice, NK cytoactive measurement result are all positive.This shows that pharmaceutical composition of the present invention has the function of enhancing immunity.
The pharmaceutical composition experimental result of the present invention that oral administration gives various dose shows, model control group rat femur dry weight and sham operated rats relatively have remarkable reduction, and have difference (P＜0.01) positive controls and model control group comparison femur dry weight on the statistics that increase is arranged, and significant difference (P＜0.01) is arranged; The basic, normal, high dosage group of pharmaceutical composition of the present invention femur dry weight and model control group relatively have dominance difference (P＜0.05 or P＜0.01), and each organizes rat femur length does not have significant difference (P＞0.05).There were significant differences (P＜0.01) with the model control group ratio for sham operated rats rat femur mid point and femur metaphysis bone density (BMD), bone mineral content (BMC); Relatively there were significant differences (P＜0.01) with model control group for positive controls rat femur mid point and femur metaphysis bone density (BMD), bone mineral content (BMC); Relatively there were significant differences (P＜0.05 or P＜0.01) with model control group for the middle and high dosage group of pharmaceutical composition of the present invention rat femur mid point and femur metaphysis bone density (BMD), bone mineral content (BMC); Relatively there were significant differences (P＜0.01) for sham operated rats rat bone calcium content and model control group, and positive controls and the middle and high dosage group of pharmaceutical composition of the present invention rat bone calcium content and model control group relatively have significant difference (P＜0.05 or P＜0.01).Therefore pharmaceutical composition of the present invention has the effect that increases the rat bone density function.
Following experimental example and embodiment are used to further specify but are not limited to the present invention.
Experimental example 1 capsule clinical verification of the present invention
One, diagnostic criteria:
1. all disease diagnostic criterias before and after the menopause:
According to the understanding of the traditional Chinese medical science to all disease pathogenesis before and after the menopause, and with reference to national standard, industry standard, institution of higher learning's Chinese medicine teaching material and Epidemiological study result, draft card and see soreness of the waist and knees, dizzy headache, forgetful cardiopalmus, insomnia is easily waken up, menoxenia, alopecia, poliosis increases, tooth gets loose, the tinnitus dim eyesight, hyposexuality, pudendum is dry and astringent, the whole body bone is painful or have edema concurrently, irritated irritability, skin itching, nape aching, articular instability, throat discomfort, constipation with dry stool, nocturia increases, warm sweating, these symptoms or be the syndrome person of appearance for a long time or temporarily, the women in age 40-60 year.
2. Western medicine diagnose standard: the perimenopausal syndrome diagnostic criteria that health ministry is issued.
(1) clinical manifestation: 1. menoxenia; 2. nervousness, emotional lability, the irritability excitement, depressed suspicious; 3. neural mental symptom: hectic fever, hyperhidrosis, insomnia and dreamful sleep; 4. urogenital tract changes: vagina drying, dyspareunia, frequent micturition incontinence; 5. cardiovascular disorder changes: uncomfortable in chest, and chest pain, cardiopalmus; 6. osteoporosis: whole body or local osteodynia, easily fracture.
(2) the laboratory endocrine is checked: 1. gonadal hormone obviously descends; 2. promoting sexual gland hormone raises; 3. prolactin antagonist descends.
Possess in 6 of the clinical manifestations wherein more than 2, add lab testing (1) or (2), and can get rid of due to other disease that age 40-60 year women is diagnosable to be climacteric syndrome.
3. include standard in: the 40-60 year women who meets above-mentioned Chinese and western medicine diagnostic criteria just can include in.
4. exclusion standard: though meet the standard of including in, one of following situation person is arranged, should be excluded in outside this test.
1. suffer from psychosis or nervous system disease person; 2. hyperthyroidism person is arranged; 3. organic cardiovascular disease person; 4. once take sex hormone drug closely over the past half year and comprised contraceptive.
5. rejecting standard: meet and fail to treat on request or the examiner after the standard of including in is participated in test.
Two, test method and observation index:
1. trial drug:
1.1. capsule of the present invention: medicament composition capsule preparation of the present invention is the capsule of interior dress sepia powder content.
1.2. LONGFENGBAO JIAONANG: the pure Chinese medicinal preparation that the strange star in Guangzhou pharmaceutical factory produces.
1.3. FUFUCHUN capsule: the compound Western medicine preparation that the Beijing Leibo Pharmaceutical Factory produces contains estrogen, progestogen, calcium and vitamin A, D, E etc.Every contains ethinylestradiol 0.625mg, medroxyprogestetone acetate 0.25mg.Main effect and purposes are the theories according to Hormone Replacement Therapy, are women's complementing estrogen, progesterone, calcium and the vitamin etc. more than 40 years old.
1.4. Cebo-Caps: form by no pharmacological action medical starch and capsule that the strange star in Guangzhou pharmaceutical factory provides.Use as blank.
Double-blind method is adopted in this test, by the personnel that do not participate in this research, with Cebo-Caps, FUFUCHUN capsule, LONGFENGBAO JIAONANG and the capsule of the present invention that is loaded in appearance color and the big or small identical capsule, by the dose pack of 30 day course of treatment, be numbered No. 1 medicine, No. 2 medicines, No. 3 medicines and No. 4 medicines and use for test.Patient and doctor and research worker did not all know respectively to number the particular content of medicine before this research finishes, to reduce artificial factor.
2. the conventional administration of dividing into groups
Clinical gynecologial examination: 1. routine examination: check pudendum and vagina; 2. vagina pH value: with the pH value of the reagent paper test vaginal secretions of pH 4-6.
The laboratory assay index is checked: the I. hormonal readiness: interstitialcellstimulating hormone (ICSH) (LH), short follicle generate plain (FSH), estrogen (E2), progesterone (P) and testosterone (T); II. cardiovascular function: Endothelin (ET), atrial natriuretic peptide (ANP), neuropeptide tyrosine (NPY) and calcitonin-gene-related peptide (CGRPH); III. bone metabolism: Bone Gla protein (BGP), calcitonin (CT), calcium (Ca) T, phosphorus (P), interleukin-6 (IL-6) and alkali phosphatase (ALP);
IV. blood lipid metabolism: triglyceride (TG), T-CHOL (TC), high density lipoprotein (HDL), low density lipoprotein, LDL (LDL), ApoA 1 (ApoA1) and apo-B (ApoB).
3. curative effect determinate standard: 1. cure: the symptom complete obiteration; 2. produce effects: symptom disappears substantially; 3. effective: symptom obviously alleviates or takes a turn for the better; 4. invalid: symptom does not have obviously good alleviate or poorer; Three,
Result of the test
Case is collected: from December in 1999 on May 30th, 1 day 1, collect to meet altogether and include standard case 101 examples in, wherein 21 examples are taken medicine on request and are rechecked and reject because of failing, surplus 80 examples for statistical analysis, each component cloth is as follows: (the routine number of individual inspection project can reduce to some extent because of blood preparation is not enough).
Age mean difference of each group not significantly (F=1.88, P=0.320), the menopause proportional difference is not remarkable yet; Each organizes experimenter's 19 clinical symptoms curative effects and significance test result.Compare with placebo group, the treatment that Chinese medicine and western medicine is three groups all can obviously improve these 17 clinical symptoms.In treatment total effective rate of each group, higher with capsule group of the present invention (all having statistical significance) to the treatment total effective rate of 17 symptoms wherein more than 84%.Wherein the effective percentage to symptoms such as exciting irritability, depressed suspicious, headache, tinnitus, gastrocnemius spasm and pain, lassitude and weak, osteoarthrosis pain and urine are anxious frequently is 100%; Each is organized an experimenter woman corpse or other object for laboratory examination and chemical testing and levies the curative effect comparative result.To being significantly improved after treatment of leucorrhea character, show that three groups of treatments of Chinese medicine and western medicine can significantly improve the leucorrhea character; Each organize the experimenter take medicine before and after in the serum gonadal hormone and the horizontal result of variations of promoting sexual gland hormone show, estrogen level significantly descends at placebo and LONGFENGBAO group, FUFUCHUN and capsule of the present invention are treated the estrogen level that then raises, and the increasing degree of invention capsule is bigger; Short follicle generated plain significantly reduction after capsule of the present invention was taken medicine, and only slightly descended in the FUFUCHUN group, and variations of all the other each groups are not remarkable; Each organize the experimenter take medicine before and after the horizontal significant change assay of bone metabolism in the serum.The result shows, the Chinese medicine and western medicine group treatment serum osteocalcin level that all can significantly raise, and two kinds of treatments by Chinese herbs can also significantly reduce the level of serum interleukin-6.FUFUCHUN fails significantly to reduce the interleukin-6 level; Each organize the experimenter take medicine before and after the blood lipid metabolism level change in twos that the significance test result shows that Capsules group of the present invention has the effect of remarkable lifting high density lipoprotein and ApoA between group, LONGFENGBAO has the effect of remarkable hypercholesterolemia reducing.FUFUCHUN has the effect of high density lipoprotein increasing, with capsule of the present invention but there is not marked difference; And the phenomenon that placebo group also has apolipoprotein obviously to raise, but its increasing degree significantly is lower than Capsules group of the present invention; Western medicines in treatment all can significantly reduce plasma ET, rising atrial natriuretic peptide and neuropeptide tyrosine level.Compare with placebo group, the size that reduces the Endothelin effect is followed successively by Capsules group of the present invention, FUFUCHUN group and LONGFENGBAO group; The size of rising atrial natriuretic peptide effect is followed successively by the LONGFENGBAO group, FUFUCHUN group and Capsules group of the present invention; The effect size of rising neuropeptide tyrosine is followed successively by Capsules group of the present invention, LONGFENGBAO group and FUFUCHUN group; Each organize the experimenter take medicine before and after Kupperman scoring total value mean change and in twos the group difference assay show, after the Kupperman scoring total value treatment of each group remarkable reduction is arranged all, but significantly relatively placebo group is big for the amplitude that the Chinese medicine and western medicine matched group reduces, and the range of decrease of Capsules group of the present invention is then maximum; Each organize the experimenter take medicine before and after the scoring of clinical symptoms determining the pathogenesis of ZANG-FU disease based on the differentiation of symptoms and signs change and in twos the group difference result show, the dirty dialectical scoring of every traditional Chinese medical science after each group treatment all has remarkable decline, but decline scope, placebo group is obviously not as the Chinese medicine and western medicine matched group, and western medicine group is again not as good as Capsules group of the present invention.With placebo group relatively, it is the most remarkable that Capsules group of the present invention is improved the suffer from a deficiency of the kidney effect of all disease scorings of each pattern of syndrome, fall is respectively deficiency of the kidney yin, deficiency of kidney-QI, kidney insufficiency.Capsule of the present invention improves the curative effect of all disease scorings of deficiency of kidney-QI obviously than three matched groups all high (P＜0.05).Improving liver is aspect all disease scorings, and Capsules group of the present invention is best, and being significantly higher than three matched groups (P＜0.05) is aspect all disease scorings improving spleen, and Capsules group of the present invention is best, is the LONGFENGBAO group secondly.Comprehensively improving kidney liver heart spleen four is aspect all disease overall scores, best with capsule of the present invention, is followed successively by the LONGFENGBAO group then, the FUFUCHUN group.
Four, conclusion (of pressure testing):
By above every pilot project, conclusion is as follows:
In 19 symptoms of observing, 17 improvement that statistical significance is all arranged are arranged after each group treatment, but the treatment total effective rate of test group and Chinese medicine and western medicine contrast treatment group is all significantly than placebo group height.Each group treatment all can significantly reduce all disease score values of the five internal organs and Kupperman score value, but in, the range of decrease of western medicine is significantly greater than placebo group.For related symptoms and all disease score values of suffering from a deficiency of the kidney of suffering from a deficiency of the kidney, the improvement degree of capsule of the present invention and LONGFENGBAO is all remarkable than Western medicine FUFUCHUN HRT treatment, and capsule of the present invention is better than the curative effect of LONGFENGBAO on most of symptoms and index.Capsule group of the present invention is improved the scoring of all disease of deficiency of kidney-QI good than Chinese medicine and western medicine matched group evident in efficacy, but Chinese medicine capsule of the present invention has more the advantage of no hormone side effect.
Following embodiment all can realize the described effect of above-mentioned experimental example.
The specific embodiment
Embodiment 1: the preparation of capsule
Herba Epimedii 25kg Fructus Ligustri Lucidi 15kg Rhizoma Polygonati Odorati 10kg Semen sojae atricolor 10kg
Flos Sophorae 10kg Radix Astragali 2.5kg Radix Angelicae Sinensis 5kg Fructus Lycii 5kg
Fructus Corni 5kg Radix Rehmanniae Preparata 5kg Radix Polygoni Multiflori 5kg freeze-dried royal jelly powder 2.5kg.
Get the above-mentioned raw materials medicine, add conventional adjuvant, make powder and go into capsule according to common process decocting in water, precipitate with ethanol, oven dry pulverizing.
Embodiment 2: the preparation of capsule
Herba Epimedii 16kg Fructus Ligustri Lucidi 18kg Rhizoma Polygonati Odorati 6kg Semen sojae atricolor 14kg
Flos Sophorae 7kg Radix Astragali 4kg Radix Angelicae Sinensis 2kg Fructus Lycii 9kg
Fructus Corni 3kg Radix Rehmanniae Preparata 8kg Radix Polygoni Multiflori 4kg freeze-dried royal jelly powder 4kg.
Get the above-mentioned raw materials medicine, add conventional adjuvant, make powder and go into capsule according to common process decocting in water, precipitate with ethanol, oven dry pulverizing.
Embodiment 3: the preparation of capsule
Herba Epimedii 32kg Fructus Ligustri Lucidi 12kg Rhizoma Polygonati Odorati 14kg Semen sojae atricolor 6kg
Flos Sophorae 13kg Radix Astragali 2kg Radix Angelicae Sinensis 9kg Fructus Lycii 2kg
Fructus Corni 8kg Radix Rehmanniae Preparata 3kg Radix Polygoni Multiflori 7kg freeze-dried royal jelly powder 2kg.
Get the above-mentioned raw materials medicine, add conventional adjuvant, make powder and go into capsule according to common process decocting in water, precipitate with ethanol, oven dry pulverizing.
Embodiment 4: the preparation of granule
Herba Epimedii 25kg Fructus Ligustri Lucidi 15kg Rhizoma Polygonati Odorati 10kg Semen sojae atricolor 10kg
Flos Sophorae 10kg Radix Astragali 2.5kg Radix Angelicae Sinensis 5kg Fructus Lycii 5kg
Fructus Corni 5kg Radix Rehmanniae Preparata 5kg Radix Polygoni Multiflori 5kg freeze-dried royal jelly powder 2.5kg.
Get the above-mentioned raw materials medicine, add conventional adjuvant, make granule according to common process.
Embodiment 5: the preparation of tablet
Herba Epimedii 16kg Fructus Ligustri Lucidi 18kg Rhizoma Polygonati Odorati 6kg Semen sojae atricolor 14kg
Flos Sophorae 7kg Radix Astragali 4kg Radix Angelicae Sinensis 2kg Fructus Lycii 9kg
Fructus Corni 3kg Radix Rehmanniae Preparata 8kg Radix Polygoni Multiflori 4kg freeze-dried royal jelly powder 4kg.
Get the above-mentioned raw materials medicine, add conventional adjuvant, make tablet according to common process.
Embodiment 6: the preparation of oral liquid
Herba Epimedii 32kg Fructus Ligustri Lucidi 12kg Rhizoma Polygonati Odorati 14kg Semen sojae atricolor 6kg
Flos Sophorae 13kg Radix Astragali 2kg Radix Angelicae Sinensis 9kg Fructus Lycii 2kg
Fructus Corni 8kg Radix Rehmanniae Preparata 3kg Radix Polygoni Multiflori 7kg freeze-dried royal jelly powder 2kg.
Get the above-mentioned raw materials medicine, add conventional adjuvant, make oral liquid according to common process.
Embodiment 7: the preparation of lyophilized injectable powder
Herba Epimedii 16kg Fructus Ligustri Lucidi 12kg Rhizoma Polygonati Odorati 14kg Semen sojae atricolor 13kg
Flos Sophorae 7kg Radix Astragali 2kg Radix Angelicae Sinensis 9kg Fructus Lycii 8kg
Fructus Corni 3kg Radix Rehmanniae Preparata 2kg Radix Polygoni Multiflori 7kg freeze-dried royal jelly powder 4kg.
Get the above-mentioned raw materials medicine, add conventional adjuvant, be prepared into lyophilized injectable powder according to common process.
Embodiment 8: the preparation of capsule
Herba Epimedii 32kg Fructus Ligustri Lucidi 19kg Rhizoma Polygonati Odorati 4kg Semen sojae atricolor 6kg
Flos Sophorae 13kg Radix Astragali 4kg Radix Angelicae Sinensis 2kg Fructus Lycii 3kg
Fructus Corni 8kg Radix Rehmanniae Preparata 9kg Radix Polygoni Multiflori 4kg freeze-dried royal jelly powder 2kg.
Get the above-mentioned raw materials medicine, add conventional adjuvant, make powder and go into capsule according to common process decocting in water, precipitate with ethanol, oven dry pulverizing.
Claims (8)
1. pharmaceutical composition for the treatment of female dimacteric syndrome and slow down aging is characterized in that this pharmaceutical composition crude drug consists of:
Herba Epimedii 15-35 weight portion Fructus Ligustri Lucidi 10-20 weight portion Rhizoma Polygonati Odorati 5-15 weight portion
Semen sojae atricolor 5-15 weight portion Flos Sophorae 5-15 weight portion Radix Astragali 1-5 weight portion
Radix Angelicae Sinensis 1-10 weight portion Fructus Lycii 1-10 weight portion Fructus Corni 1-10 weight portion
Radix Rehmanniae Preparata 1-10 weight portion Radix Polygoni Multiflori 1-10 weight portion freeze-dried royal jelly powder 1-5 weight portion.
2. pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition crude drug consists of:
Herba Epimedii 25 weight portion Fructus Ligustri Lucidi 15 weight portion Rhizoma Polygonati Odorati 10 weight portions
The Semen sojae atricolor 10 weight portion Flos Sophoraes 10 weight portion Radixs Astragali 2.5 weight portions
Radix Angelicae Sinensis 5 weight portion Fructus Lycii 5 weight portion Fructus Corni 5 weight portions
Radix Rehmanniae Preparata 5 weight portion Radix Polygoni Multiflori 5 weight portion freeze-dried royal jelly powders 2.5 weight portions.
3. pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition crude drug consists of:
Herba Epimedii 16 weight portion Fructus Ligustri Lucidi 18 weight portion Rhizoma Polygonati Odorati 6 weight portions
The Semen sojae atricolor 14 weight portion Flos Sophoraes 7 weight portion Radixs Astragali 4 weight portions
Radix Angelicae Sinensis 2 weight portion Fructus Lycii 9 weight portion Fructus Corni 3 weight portions
Radix Rehmanniae Preparata 8 weight portion Radix Polygoni Multiflori 4 weight portion freeze-dried royal jelly powders 4 weight portions.
4. pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition crude drug consists of:
Herba Epimedii 32 weight portion Fructus Ligustri Lucidi 12 weight portion Rhizoma Polygonati Odorati 14 weight portions
The Semen sojae atricolor 6 weight portion Flos Sophoraes 13 weight portion Radixs Astragali 2 weight portions
Radix Angelicae Sinensis 9 weight portion Fructus Lycii 2 weight portion Fructus Corni 8 weight portions
Radix Rehmanniae Preparata 3 weight portion Radix Polygoni Multiflori 7 weight portion freeze-dried royal jelly powders 2 weight portions.
5. as the arbitrary described pharmaceutical composition of claim 1-4, it is characterized in that getting the above-mentioned composition crude drug, add conventional adjuvant,, make capsule, granule, tablet, oral liquid, aqueous injection or lyophilized injectable powder according to common process.
6. as the arbitrary described preparation of drug combination method of claim 1-4, it is characterized in that this method is: get crude drug, add conventional adjuvant,, make capsule, granule, tablet, oral liquid, aqueous injection or lyophilized injectable powder according to common process.
7. as the application of the arbitrary described pharmaceutical composition of claim 1-4 in the medicine of preparation treatment female dimacteric syndrome.
8. has application in slow down aging, enhancing immunity or the bone density improving medicine as the arbitrary described pharmaceutical composition of claim 1-4 in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007103020416A CN101461895B (en) | 2007-12-20 | 2007-12-20 | Medicament composition for treating female climacteric syndrome and delaying age |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007103020416A CN101461895B (en) | 2007-12-20 | 2007-12-20 | Medicament composition for treating female climacteric syndrome and delaying age |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101461895A CN101461895A (en) | 2009-06-24 |
| CN101461895B true CN101461895B (en) | 2010-12-08 |
Family
ID=40802831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007103020416A Active CN101461895B (en) | 2007-12-20 | 2007-12-20 | Medicament composition for treating female climacteric syndrome and delaying age |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101461895B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103272119A (en) * | 2013-05-03 | 2013-09-04 | 甘肃中脉生物医药科技有限公司 | Traditional Chinese medicine preparation for treating osteoporosis |
| CN105816638A (en) * | 2016-04-19 | 2016-08-03 | 文学忠 | Composition for delaying female climacteric syndrome and preparation method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1100948A (en) * | 1994-03-01 | 1995-04-05 | 段炜 | Health and beauty oral liquor for female |
| CN1178116A (en) * | 1997-07-12 | 1998-04-08 | 迟经惠 | Medicine for tonifying yin for female |
| CN1184659A (en) * | 1997-11-14 | 1998-06-17 | 张锡昆 | Traditional Chinese medicine for invigorating kidney and strengthening the spleen and stomach |
| CN1293992A (en) * | 1999-10-21 | 2001-05-09 | 陈德才 | Medicine 'Buyuan Jianmei Wan' |
| CN1478509A (en) * | 2003-03-28 | 2004-03-03 | 刘晓雷 | Health-care liquid |
-
2007
- 2007-12-20 CN CN2007103020416A patent/CN101461895B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1100948A (en) * | 1994-03-01 | 1995-04-05 | 段炜 | Health and beauty oral liquor for female |
| CN1178116A (en) * | 1997-07-12 | 1998-04-08 | 迟经惠 | Medicine for tonifying yin for female |
| CN1184659A (en) * | 1997-11-14 | 1998-06-17 | 张锡昆 | Traditional Chinese medicine for invigorating kidney and strengthening the spleen and stomach |
| CN1293992A (en) * | 1999-10-21 | 2001-05-09 | 陈德才 | Medicine 'Buyuan Jianmei Wan' |
| CN1478509A (en) * | 2003-03-28 | 2004-03-03 | 刘晓雷 | Health-care liquid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101461895A (en) | 2009-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103751529A (en) | Traditional Chinese medicine composition for treating female postmenopausal osteoporosis and preparation method thereof | |
| CN102526326B (en) | Traditional Chinese medicine for treating postmenopausal osteoporosis and preparation method thereof | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
| CN103550476B (en) | A kind of pharmaceutical composition for the treatment of postmenopausal osteoporosis and preparation method thereof | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN101138597B (en) | Traditional Chinese medicine preparation for preventing and controlling osteoporosis and method of preparing the same | |
| CN1259955C (en) | Chinese medicine preparation for treating climacteric metancholia of women | |
| CN101461895B (en) | Medicament composition for treating female climacteric syndrome and delaying age | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103356932B (en) | A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia | |
| CN101461894B (en) | Medicament composition for treating female climacteric syndrome and delaying age | |
| CN100560089C (en) | Be used for the treatment of osteoporotic Chinese medicine preparation | |
| CN105943651A (en) | Traditional Chinese medicine composition for treating premature ovarian failure, and application thereof | |
| CN109528980A (en) | A kind of Chinese medicine composition and its pharmacy application for treating Ovary reserve decline disease | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| CN112773865A (en) | Composition with kidney tonifying and menstruation regulating functions and application | |
| CN105267538A (en) | Pilose antler paste for treatment of irregular menstruation and preparation method thereof | |
| CN110141656A (en) | A kind of Fuke Tiaojing blood-nourishing Chinese medicine composition and preparation method thereof | |
| CN110237161A (en) | Drug and its preparation method and application for treating menopausal syndrome | |
| CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
| CN103301374B (en) | Pharmaceutical composition for treating postpartum non-specificity vaginitis | |
| CN105727237A (en) | Folium artemisiae argyi-containing pharmaceutical composition for treating amenorrhea | |
| CN105250754A (en) | Traditional Chinese medicine composition for relieving menopausal symptoms and application of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |